AMED GRiT selects eight global rare-disease development programs
Eight Japanese-led programs were selected for global clinical development support, including Phase III, CAR-T and oncolytic-virus programs.
→2026.10.19｜Early Consideration｜Cancer drugs and companion diagnostics
2026.10.16｜Committee endorsement｜Stemirac full approval
2026.10.17｜Medical congress｜75th JSA meeting
2026.02.27｜Basic research｜Mouse testis organoid
2026.10.15｜Observational study｜Discharge UACR and cardiorenal risk
2026.10.14 | Basic research | Large-scale centromere analysis
NEW / 2026.10.13 / PRECLINICAL
Needle-free inner-ear mRNA delivery shows lower-impact potential in guinea pigs
A jet device delivered mRNA to the middle ear in guinea pigs with smaller tympanic injury. This is preclinical animal research, not an available human treatment.
Read →NEW / 2026.10.13 / BASIC RESEARCH
University of Tokyo develops three tools for RNA–protein interactions
Three CRISPR/Cas13-based tools record, measure and explore RNA–protein interactions. This is basic research, not a diagnostic or clinical treatment.
Read →MEDICAL INFORMATION
Medical Information
English-language LINK MT pages on Japanese medicine, new drugs, clinical research and international-patient pathways.
AMED Healthtech Challenge 2026
Call published 8 October 2026; deadline 4 November.
→Atopic dermatitis: understanding the itch-inflammation loop
A long-term guide to skin barrier dysfunction, type-2 inflammation, sensory pathways and emerging lipid biology in atopic dermatitis.
→Atopic dermatitis itch: a PLA2G2F/P-LPE amplification pathway
Japanese researchers report that P-LPE generated by PLA2G2F may amplify inflammation and itch in atopic dermatitis. This is mechanistic research, not an approve
→Mutation-specific correction of SOD1 in familial ALS iPS cells
Prime and base editing were optimized for two SOD1 variants in human iPS cells. This is laboratory research, not a clinical treatment.
→CiRA–Zurich next-generation medicine lab
A joint research platform spanning iPS, tissue engineering and translational medicine.
→Conditional and time-limited approval
How Japan's conditional, time-limited approval differs from full approval, reimbursement and clinical trials.
→Severe heart failure due to ischemic cardiomyopathy
Causes, standard therapy and the limited current role of Japan's iPSC cardiomyocyte sheet for severe ischemic heart failure.
→CheckMate 648: five-year follow-up of nivolumab combinations in esophageal cancer
NCC reports long-term results from the phase III CheckMate 648 trial in advanced or recurrent esophageal squamous-cell carcinoma.
→Oveporexton: Japan-approved OX2R agonist for narcolepsy type 1
Oveporexton (Orzeyful in Japan) was approved on August 24, 2026 for adults with narcolepsy type 1. This page separates approval from pricing, launch and real-wo
→Anamorelin: posaconazole added as a contraindication
PMDA precaution revision dated 8 October 2026.
→RiHEART: first transplantation after Japan's insurance listing
Evidence-focused review of Japan's first RiHEART transplantation after national insurance listing: indication, conditional approval, eight-patient evidence and
→A dual gate for mRNA: cancer-cell selectivity plus light control
A polymer enabled light-triggered mRNA expression in cancer cells and a mouse tumor model. Human efficacy and safety are unknown.
→Contact Cao Zheng